Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory.

Slides:



Advertisements
Similar presentations
Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.
Advertisements

The Home INR Study (THINRS): Home INR Monitoring as Effective as Clinic-Based Care AK Jacobson, MD American Heart Association 2008 Scientific Sessions:
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Clinical Impact of the IHS Anticoagulation Training Program USPHS Scientific and Training Symposium May 2010 LT Nicholas Sparrow, Pharm.D. PGY1 Pharmacy.
Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU- PACT) Warfarin.
Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.
ARISTOTLE TTR Subanalysis
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Identifying the Presence of Peripheral Artery Disease in Patients With and Without Diabetes Lori Brown, PharmD and Charles Herring, PharmD, BCPS, CPP University.
Dr : Osama Badry Cardiology /Anticogaulation Coordinator Incharge of Anticoagulation Service AWH-HMC/Qatar.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
Corticosteroid dosing in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS, Takova D. Wallace, Pharm.D. Candidate 2014, Ryan E.
Evaluating clinical pharmacist impact on diabetes control: outcomes on hemoglobin A1c Mark Amoo PharmD Candidate, Dalton Walsh PharmD Candidate, Kalyani.
INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,
Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Praxbind® - Idarucizumab
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
ACCP Cardiology PRN Journal Club 1. Announcements Thank you attending the ACCP Cardiology PRN Journal Club – Thank you if you attended before or have.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Background Medication Reconciliation is a formal process in which accurate and complete medication information is transferred at interfaces of care. Prospective.
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Comparison of pharmacy technician versus nurse obtained medication histories in the emergency department Marija Markovic, Pharm.D. PGY-1 Pharmacy Practice.
Establishment of An Economically Viable Comprehensive Multidisciplinary Anticoagulation Program In An Academic-Based Residency Lilika White MD, Andrew.
Pharmacist Impact on Patient Mortality and Advanced Cardiac Life Support Guideline Compliance During In-Hospital Cardiac Arrest Joseph Cavanaugh, PharmD.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Impact of Integrating Family Medicine and Pharmacy in an Interdisciplinary Anti-Coagulation Program B. Timothy Kodsi M.D., Michael Machek M.D., Keiran.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Length of Hospital Stay for Bleeding Among Adults with Atrial Fibrillation Treated with Warfarin, Dabigatran, or Rivaroxaban Blake Charlton MD1, Gboyega.
Cara Coffelt, PharmD PGY-1 Pharmacy Resident
Ryan Sparks, PharmD, BCPS PGY2 Cardiology Resident
Efficacy of Renally Adjusted Treatment Dose Enoxaparin in Obese Patients with Severe Renal Impairment Alexas Polk, PharmD PGY-1 Pharmacy Resident St. Joseph’s/Candler.
Sample Journal Club Your Name Here.
Figure 1: Flow diagram of study selection.
Presenter: Meng-Jiun Chiou Present data: 2017/7/10
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Exploring Factors Associated with Preferential Prescribing of Apixaban Over Warfarin in Patients with Non-Valvular Atrial Fibrillation Scott McColgana,
The Impact of Technology on Patient Perceptions of Primary Care Provider Empathy Christopher Terry, PharmD PGY1 Pharmacy Resident – Ambulatory Care Mission.
Impact Of Comorbidities and Concomitant Medication Administration On Inpatient Management Of Warfarin Therapy William Wheeler, PharmD PGY1 Pharmacy Resident.
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Efficacy and Safety of Dabigatran vs
Evaluation of Four Factor Prothrombin Complex Concentrate
Ortho Warfarin Dosing Protocol
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.
by Kueiyu Joshua Lin, Daniel E. Singer, Robert J
Aug, 2016.
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
New Strategies to Prevent CV Events After Hospital Discharge
Selecting NOACs for High-Risk Patients
GHS Outpatient Enoxaparin Program
Pradaxa Jeopardy Copyright 2001.
ACC 2003 Late Breaking Trials
Presentation transcript:

Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory Care Mission Hospital and Mountain Area Education Center (MAHEC) Asheville, North Carolina

Disclosure Statement None of the following individuals involved in this project have anything to disclose concerning possible financial or personal relationships with commercial entities (or their competitors). –Resident: Ashley Pokallus, PharmD –Project Advisor: Bill Hitch, PharmD, BCPS, CPP –Statistician: Shelley Galvin, MA

Background million US patients are using warfarin Narrow therapeutic index makes monitoring essential –Bleed rate 1-3% per patient year –Thromboembolism rate 2% per patient year SPORTIF III and V demonstrated patients with time in therapeutic range (TTR) <60% had poor outcomes Trials have shown that management of anticoagulation by hospital- based clinics is better than that in primary care offices

Mountain Area Health Education Center

MAHEC Clinic Structure—Silo Approach Anticoagulation Clinic – 2 half days a week – 2 primary providers – POC monitoring – 20 minute appointment slots – Pharmacy resident involvement Pharmacotherapy Clinic – 7 half days a week – 2 primary providers – 20 minute appointment slots – Pharmacy resident involvement Pharmacotherapy Clinic Anticoagulation Clinic

MAHEC Clinic Structure—Integrated Approach Pharmacotherapy Clinic (including anticoagulation management) – 9 half days a week – 4 primary providers – POC monitoring – 20 minute appointment slots – Pharmacy resident involvement Pharmacotherapy Clinic

Purpose To compare impact of clinic structure change in terms of efficacy of anticoagulation management, by evaluating TTR, and patient satisfaction.

Objectives Primary –Compare TTR between the two clinic structures Secondary –Consider change in patient satisfaction between the two clinic structures –Evaluate rate of bleeding and thromboembolism between the two clinic structures –Assess the variability in providers between the two clinic structures

Methodology Study Design: IRB-approved, retrospective, longitudinal chart review –Silo Approach—May 2014-November 2014 –Integrated Approach—May 2015-November 2015 –TTR calculated based on Rosendaal Method –Provider Consistency Anonymous Patient Satisfaction Survey –8 questions relating to clinic changes and quality of care –Administered between October 2015-November 2015

Methodology Inclusion Criteria –Being treated with warfarin at Biltmore Clinic prior to May 2014 Exclusion Criteria –Gap in care >8 weeks –Initiation of therapy after May 2014 –Completion of therapy prior to November 2015 –Transfer of care during study period –Managed at a MAHEC clinic site other than Biltmore Clinic

59 patients identified from Coumadin Registry TTR Study Analysis of TTR for 32 patients 27 patients excluded (14 initiated therapy during study period 13 gap in care >8 weeks) Patient Satisfaction Survey Administered to 19 patients during appointment

Baseline Characteristics n=32 Age—median (range)77 (52-96) Medications—median (range)8 (2-20) Gender—female, n (%)18 (56.3) Race, n (%) White/Non-Hispanic Black Unknown 24 (75.0) 1 (3.1) 7 (21.9) History of stroke, n (%) History of major bleed, n (%) 5 (15.6) 1 (3.1) n=32 Indication for warfarin therapy, n (%) Atrial fibrillation Deep vein thrombosis (DVT) Pulmonary embolism (PE) Mechanical valve Other 28 (87.5) 4 (12.5) 1 (3.1) 3 (9.6) INR Goal, n (%) 2 to to 3.5 Other 29 (90.6) 2 (6.3) 1 (3.1)

Results—TTR Analysis n=32 Silo ModelIntegrated Model p-value TTR (Median)71.3%71.9%0.638 Composite Thromboembolism, n (%)2 (6.1%)0 (0%)0.5 Composite Bleeding, n (%)1 (3%)0 (0%)1.00

Results—TTR Analysis p=0.791 Number of Patients, n=32

Results—Patient Satisfaction n=19

Results—Patient Satisfaction n=19 Percentage of Patients

Results—Provider Consistency Provider Consistency n=32SiloIntegratedp-value Median (min-max)44.4% ( %) 38.1% ( %) 0.226

Results—Provider Consistency

↑TTR ↑Provider Consistency ↓ TTR ↓ Provider Consistency ↑ TTR ↓ Provider Consistency ↓ TTR ↑ Provider Consistency

Discussion Primary endpoint –TTR did not significantly change between the two clinic structures Secondary endpoints –Patients are satisfied with the care they are receiving for their anticoagulation at MAHEC’s Biltmore Clinic –Provider consistency did not change significantly between the two clinics Association between decreased provider consistency and decreased TTR –Nonsignificant composite outcome

Limitations Small sample size Large number of patients excluded from the study Relatively short time frame Different subset of patients in each arm Possibility of social desirability bias

Conclusion Current clinic model seems to be effective and safe, and patients are satisfied with care.

Self-assessment question Question –What is one thing that can be learned by comparing these patient care structures? Answer –TTR did not change despite change in clinic structure –Perceptions of wait times and clinic availability improved –Both models have value

Patient Satisfaction Survey

References 1.Carlson B. Declaring war on warfarin misdosing. Biotechnol Healthc 2008; 5(2): Available from: 2.Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowney PR, Chang P, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Available from: Rosendaal Method. INRPRO. Accessed 8/25/2015. Accessed from: White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomizeed to warfarin therapy according to anticoagulant control results from SPORTIF III and V. Arch Intern Med, , pp Palareti G. Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. Semin Hematol Apr;51(2):

Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory Care Mission Hospital—1 Hospital Drive Asheville, North Carolina